Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Author Cunningham, Anthony L. Google Scholar
Heineman, Thomas C. Google Scholar
Lal, Himal Google Scholar
Godeaux, Olivier Google Scholar
Chlibek, Roman Google Scholar
Hwang, Shinn-Jang Google Scholar
McElhaney, Janet E. Google Scholar
Vesikari, Timo Google Scholar
Andrews, Charles Google Scholar
Choi, Won Suk Google Scholar
Esen, Meral Google Scholar
Ikematsu, Hideyuki Google Scholar
Choma, Martina Kovac Google Scholar
Pauksens, Karlis Google Scholar
Ravault, Stephanie Google Scholar
Salaun, Bruno Google Scholar
Schwarz, Tino F. Google Scholar
Smetana, Jan Google Scholar
Vanden Abeele, Carline Google Scholar
Van den Steen, Peter Google Scholar
Vastiau, Ilse Google Scholar
Weckx, Lily Yin Autor UNIFESP Google Scholar
Levin, Myron J. Google Scholar
Abstract Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: >= 50

ZOE-70: >= 70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing >= 2 of 4 activation markers assessed (CD4(2+)) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD4(2+) T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained >= 5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.
Keywords varicella-zoster virus
herpes zoster vaccine
gE subunit vaccine
adjuvant system
Language English
Sponsor GlaxoSmithKline Biologicals SA
Date 2018
Published in Journal Of Infectious Diseases. Cary, v. 217, n. 11, p. 1750-1760, 2018.
ISSN 0022-1899 (Sherpa/Romeo, impact factor)
Publisher Oxford Univ Press Inc
Extent 1750-1760
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000434081100009

Show full item record


Name: WOS000434081100009.pdf
Size: 3.041Mb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account